10x Genomics is trading 10.14% higher at $83.29, with no confirmed company-specific catalyst identified for September 24.
- The rebound follows a 6.29% decline on September 23.
- Recent reports referenced earlier optimism around raised 2026 revenue guidance, a patent-infringement verdict, and the Lunit collaboration, but do not establish these as drivers of today’s move.
- The biotech sector is down, making sector or broad-market sentiment an unconvincing explanation.